Polypharmakos
Polypharmakos is a joint venture between The University of Cambridge and the Royal Botanic Gardens, Kew, leveraging extensive institutional scientific knowledge to explore and commercialize the therapeutic potential of natural extracts. They utilize a 'Nutripharma' approach spanning nutraceutical, functional food, and pharmaceutical sectors, with a focus on inflammaging. By combining AI-based machine learning with deep ethnobotanical knowledge from Kew and CABI, Polypharmakos interrogates vast libraries of plant and fungi extracts (over 8.75 million samples) to identify novel compounds that can influence inflammatory pathways. Their multi-factorial approach aims to develop safer and more effective treatments for age-related diseases, differing from conventional mono-therapies. The company also highlights the significant untapped potential in natural products, with a small percentage of plant and fungi species currently patented or fully investigated.
Polypharmakos
Polypharmakos is a joint venture between The University of Cambridge and the Royal Botanic Gardens, Kew, leveraging extensive institutional scientific knowledge to explore and commercialize the therapeutic potential of natural extracts. They utilize a 'Nutripharma' approach spanning nutraceutical, functional food, and pharmaceutical sectors, with a focus on inflammaging. By combining AI-based machine learning with deep ethnobotanical knowledge from Kew and CABI, Polypharmakos interrogates vast libraries of plant and fungi extracts (over 8.75 million samples) to identify novel compounds that can influence inflammatory pathways. Their multi-factorial approach aims to develop safer and more effective treatments for age-related diseases, differing from conventional mono-therapies. The company also highlights the significant untapped potential in natural products, with a small percentage of plant and fungi species currently patented or fully investigated.
TL;DR
Headquarters / Origin: Cambridge, UK spin-out from University of Cambridge and Royal Botanic Gardens, Kew
Focus: AI-enabled discovery of natural extracts targeting inflammaging (age-related inflammation)
Unique assets: Access to ~8.75 million validated plant and fungal extract accessions (Kew and CABI)
Stage / team size: Small team (reported employee_count: 4)
Company Overview
Problem Domain
Discovery of therapeutic and nutraceutical agents to modulate age-related inflammation (inflammaging) using natural products.
Founded
2016
Industry
Biotechnology
Tech Stack
Funding Track Record
Investor Signal
“Kew and Cambridge Enterprise listed as shareholders/strategic partners”